NuVasive(R) to Exhibit at ISASS 2013

NuVasive(R) to Exhibit at ISASS 2013 
SAN DIEGO, CA -- (Marketwire) -- 03/27/13 --  NuVasive, Inc. (NASDAQ:
NUVA), a medical device company focused on developing minimally
disruptive surgical products and procedures for the spine, is excited
to announce their participation at the 2013 International Society for
the Advancement of Spine Surgery (ISASS) Conference from Tuesday,
April 2nd, to Saturday, April 6th, 2013, at the Vancouver Convention
Centre in Vancouver, Canada, booth #212. 
ISASS is one of the most widely attended conferences by spine
surgeons throughout the world due to the robust weeklong agenda that
includes exhibits featuring innovative devices and techniques, a
cadaver course, scientific presentations, and exclusive educational
"NuVasive is pleased to exhibit our innovative technologies and
comprehensive spine portfolio at ISASS," said Pat Miles, NuVasive
President of Global Products and Services. "This year, we are excited
to introduce surgeons to several game-changing new products and
procedures, such as the PCM(R) Cervical Disc and Precept(TM) for
MAS(R) Posterior Fixation. As well, our XLIF(R), ALIF, and posterior
fixation solutions will be featured in cadaver courses organized by
ISASS, providing surgeons hands-on educational experiences and
opportunities to become more familiar with NuVasive's full product
NuVasive is scheduled to participate in the following events at

--  NuVasive Exhibit Booth #212: The NuVasive exhibit booth will feature a
    number of innovative, minimally disruptive products and procedures
    including: XLIF(R), Precept(TM), MAS(R) PLIF, Armada(R),
    Biologics, our comprehensive cervical portfolio including the
    PCM(R) Cervical Disc, and our NVM5(R)system.
--  NuVasive Sponsored Workshop: A lunch workshop will be held from 12:00
    PM to 1:30 PM on Wednesday, April 3rd, in Room 7 to discuss Maximum
    Access Surgery (MAS(R)) techniques for complex pathologies such as
    spondylolisthesis and degenerative scoliosis, kyphosis and sagittal
    balance, and tumor and trauma.
--  ISASS Organized Cadaver Course: NuVasive will participate in cadaver
    courses on April 5th from 3:30 PM to 5:30 PM (didactic session) and on
    April 6th from 7:00 AM to 1:00 PM (cadav
er lab).
--  Clinical Papers: NuVasive solutions will be featured in 14 invited
    podium presentations and numerous posters that include the latest
    research on our minimally invasive portfolio and advanced biologics.

For more information on ISASS 2013 please visit:  
For NuVasive Press Materials please visit:  
 The International Society for the Advancement of Spine
Surgery is an international, scientific and educational society
organized to discuss and assess existing strategies and innovative
ideas in the clinical and basic sciences related to spine surgery and
to enhance patient care. 
About NuVasive
 NuVasive is a medical device company focused on
developing minimally disruptive surgical products and procedurally
integrated solutions for the spine. The Company is the 4th largest
player in the $8.2 billion global spine market. NuVasive's principal
product offering is based on its Maximum Access Surgery, or MAS(R)
platform. The MAS platform combines several categories of solutions
that collectively minimize soft tissue disruption during spine
surgery with maximum visualization and safe, easy reproducibility for
the surgeon: a proprietary software-driven nerve avoidance system and
intra-operative monitoring support; MaXcess(R), a unique split-blade 
retractor system; a wide variety of specialized implants; and several
biologic products to aid in the spinal fusion process. MAS
significantly reduces surgery time and returns patients to activities
of daily living much faster than conventional approaches. Having
redefined spine surgery with the MAS platform's lateral approach,
known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has
built an entire spine franchise. With over 80 products today spanning
lumbar, thoracic and cervical applications, the Company will continue
to expand and evolve its offering predicated on its R&D focus and
dedication to outstanding service levels supported by a culture of
Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties are described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made. 
Investor Contact:
Stephan Ogilvie 
VP, Corporate Development & Investor Relations
NuVasive, Inc.
Nicole Collins
NuVasive, Inc.
Press spacebar to pause and continue. Press esc to stop.